Newsroom
New Law Goes Into Effect to Strengthen The Maryland Prescription Drug Affordability Board
04.11.2023
The Challenges Facing America’s Health Care System
Houston Public Media
03.03.2023
How a Drug Company Made $114 Billion by Gaming the U.S. Patent System
The New York Times
02.03.2023
Statement from Laura and John Arnold Following Senate Passage of the Inflation Reduction Act of 2022
08.07.2022
What’s Driving Up Medicare Part D Costs? High Brand-Name Drug Net Prices And A Shift To High-Cost Specialty Drugs
Health Affairs
04.21.2022
Save America’s Patent System
The New York Times
04.18.2022
Civica aims to launch low-cost insulin in U.S. by 2024
Reuters
03.04.2022
Though Strict, CMS Aduhelm Policy May Create Pressure For Wider Coverage
Inside Health Policy
01.12.2022
Medicare sidelines Aduhelm
Axios
01.12.2022
House Democrats find in three-year investigation that drug prices are ‘unsustainable, unjustifiable and unfair’
The Washington Post
12.10.2021
ICER Identifies Most Significant 2020 US Drug-Price Hikes Not Supported by New Clinical Evidence
ICER
11.17.2021
Without drug pricing reform, BBB will stand for ‘Biden’s Big Blunder’
The Hill
10.29.2021
Arnold Ventures’ Statement on the Removal of Drug Pricing from the Build Back Better Framework
10.28.2021
The Public Weighs In On Medicare Drug Negotiations
Kaiser Family Foundation
10.15.2021
Why We Can Have Both Innovative Drugs and Lower Drug Prices
Politico
10.15.2021
The U.S. Can Lower Drug Prices Without Sacrificing Innovation
Harvard Business Review
10.04.2021
Letting the government negotiate drug prices won’t hurt innovation
The Washington Post
09.22.2021
Group That Boosted Menendez Re-Election Now Spending To Lobby Him
New Jersey Globe
07.19.2021
